BioSyent Inc., headquartered in Mississauga, Canada, is a specialized pharmaceutical firm that was established in 2006. The company, which changed its name from Hedley Technologies Inc. in June 2006 to underscore its focus on the pharmaceutical sector, operates internationally as well as within Canada. Its business model involves identifying, acquiring or licensing, developing, and ultimately commercializing various pharmaceutical and healthcare products. The company's diverse product portfolio features several key offerings. These include the FeraMAX line of iron supplements: FeraMAX 150, an oral hematinic; FeraMAX Powder, a water-soluble oral iron supplement designed to assist in red blood cell formation; and FeraMAX Pd Therapeutic 150, which is specifically formulated for the prevention and treatment of iron deficiency anemia. Additionally, BioSyent provides Cathejell, a product utilized for both surface anesthesia and lubrication during a variety of medical procedures, such as cystoscopy, catheterization, endourethral operations, endoscopy, proctoscopy, rectoscopy, and tracheal intubation. It also helps in alleviating pain associated with conditions like cystitis and urethritis. For women's health, RepaGyn is offered as a vaginal suppository to promote the healing of vaginal mucosa and address dryness caused by menopause, stress, or chemotherapy. Similarly, Proktis-M is a rectal suppository aimed at healing the anal and rectal areas. Other notable products encompass Combogesic, intended for adults seeking relief from moderate acute pain and fever reduction. Interestingly, BioSyent also distributes Protect-It, a non-chemical, food-safe grain insecticide used as a preventative measure against insect infestations in stored grains. Furthermore, Tibella is available as a hormone replacement therapy to manage vasomotor symptoms resulting from estrogen deficiency. BioSyent distributes its products through established channels, including wholesale partners and retail pharmacy chains.